# Randomized Study of Triple Therapy vs Sildenafil Dose Optimization in Pulmonary Arterial Hypertension

Study · id `cardio:ct-nct07713914` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07713914](<https://clinicaltrials.gov/study/NCT07713914>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07713914

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 196 participants.

## Technical summary

Registry record NCT07713914. Randomized; no masking; primary purpose treatment. Start 2026-07-22 (anticipated); primary completion 2028-07-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 196 participants (planned count; ClinicalTrials.gov record NCT07713914, source copy `cardio:ctgov-nct07713914-2026-07-30`, retrieved 2026-10-31)
- Planned start: 2026-07-22 (anticipated) (ClinicalTrials.gov record NCT07713914, source copy `cardio:ctgov-nct07713914-2026-07-30`, retrieved 2026-10-31)
- Primary completion: 2028-07-01 (anticipated) (ClinicalTrials.gov record NCT07713914, source copy `cardio:ctgov-nct07713914-2026-07-30`, retrieved 2026-10-31)
- Completion: 2028-12-31 (anticipated) (ClinicalTrials.gov record NCT07713914, source copy `cardio:ctgov-nct07713914-2026-07-30`, retrieved 2026-10-31)
- Countries: Brazil (ClinicalTrials.gov record NCT07713914, source copy `cardio:ctgov-nct07713914-2026-07-30`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07713914-2026-07-30`, retrieved 2026-10-31)

## The registry's words

- Brief title: Randomized Study of Triple Therapy vs Sildenafil Dose Optimization in Pulmonary Arterial Hypertension
- Acronym: ASCEND-PAH
- Condition: Pulmonary Arterial Hypertension (PAH)
- Intervention (Drug): Prostacyclin Pathway Agent
- Intervention (Drug): Sildenafil Dose Optimization
- Lead sponsor: University of Sao Paulo General Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`)
- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)
- Registry lists this organization as the lead sponsor: University of Sao Paulo General Hospital (`cardio:org-university-of-sao-paulo-general-hospital`)

## Provenance

Content hash: dac95219f4bacf38cc32901c49566facaefdb972e4fd36ae9439acecead50fdf
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
